title: Weekly Versus Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Cervical Cancer: A Meta-Analysis.
abstract: The aim of this study was to evaluate toxicity, compliance, recurrence and the survival of weekly and triweekly cisplatin-based concomitant chemoradiation in treatment of cervical cancer.
  
  
  
  The databases were searched from 1995 until 2015 to identify eligible studies on weekly versus triweekly cisplatin chemoradiotherapy. The data were analyzed by RevMan 5.3 software.
  
  
  
  A total of 5 randomized controlled trials were included in this review. Weekly cisplatin regimen significantly reduced the incidence of Hematologic toxicity. However, there was no significantly different between the 2 arms in compliance, recurrence and the survival rate (all P >0.05).
  
  
  
  Weekly cisplatin regimen had the similar therapeutic effect as the triweekly cisplatin regimen but with less hematologic toxicity. Therefore, we recommend the weekly cisplatin 30 to 40 mg/m chemoradiotherapy as the strong candidate for the optimal cisplatin dose and dosing schedule in the treatment of locally advanced cervical cancer.
authors.affiliation: *Department of Chemoradiation Oncology, The First Affiliated Hospital of Wenzhou Medical University; †Department of Oncology, Wenzhou Hospital of Traditional Chinese Medicine, Wenzhou, Zhejiang, P.R. China.
authors.forename: Xingxing
authors.initials: X
authors.lastname: Chen
authors.forename: Haizhou
authors.initials: H
authors.lastname: Zou
authors.forename: Huifang
authors.initials: H
authors.lastname: Li
authors.forename: Ruifang
authors.initials: R
authors.lastname: Lin
authors.forename: Meng
authors.initials: M
authors.lastname: Su
authors.forename: Wenyi
authors.initials: W
authors.lastname: Zhang
authors.forename: Yongqiang
authors.initials: Y
authors.lastname: Zhou
authors.forename: Ping
authors.initials: P
authors.lastname: Zhang
authors.forename: Meng
authors.initials: M
authors.lastname: Hou
authors.forename: Xia
authors.initials: X
authors.lastname: Deng
authors.forename: Changlin
authors.initials: C
authors.lastname: Zou
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D010349:Patient Compliance; D016032:Randomized Controlled Trials as Topic; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*
chemical_list: D002945:Cisplatin